Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 3/2007

01-03-2007 | Article

Acute and selective regulation of glyceroneogenesis and cytosolic phosphoenolpyruvate carboxykinase in adipose tissue by thiazolidinediones in type 2 diabetes

Authors: T. Cadoudal, J. M. Blouin, M. Collinet, F. Fouque, G. D. Tan, E. Loizon, E. G. Beale, K. N. Frayn, F. Karpe, H. Vidal, C. Benelli, C. Forest

Published in: Diabetologia | Issue 3/2007

Login to get access

Abstract

Aims/hypothesis

Regulation of glyceroneogenesis and its key enzyme cytosolic phosphoenolpyruvate carboxykinase (PEPCK-C) plays a major role in the control of fatty acid release from adipose tissue. Here we investigate the effect of rosiglitazone on the expression of genes involved in fatty acid metabolism and the resulting metabolic consequences.

Materials and methods

Rosiglitazone was administered to Zucker fa/fa rats for 4 days and to 24 diabetic patients for 12 weeks, then mRNA expression for the genes encoding PEPCK-C, mitochondrial PEPCK, adipocyte lipid-binding protein, glycerol kinase, lipoprotein lipase and glycerol-3-phosphate dehydrogenase was examined in s.c. adipose tissue by real-time RT-PCR. Glyceroneogenesis was determined using [1−14C]pyruvate incorporation into lipids. Cultured adipose tissue explants from overweight women undergoing plastic surgery were incubated with rosiglitazone for various times before mRNA determination and analysis of PEPCK-C protein, activity and glyceroneogenesis.

Results

Rosiglitazone administration to rats induced the expression of the gene encoding PEPCK-C mRNA (PCK1) and PEPCK-C activity in adipose tissue with a resulting 2.5-fold increase in glyceroneogenesis. This was accompanied by an improvement in dyslipidaemia as demonstrated by the decrease in plasma NEFAs and triacylglycerol. In rosiglitazone-treated diabetic patients, PCK1 mRNA was raised 2.5-fold in s.c. adipose tissue. Rosiglitazone treatment of adipose tissue explants from overweight women caused a selective augmentation in PCK1 mRNA which reached a maximum of 9-fold at 14 h, while mRNA for other genes remained unaffected. Experiments with inhibitors showed a direct and transcription-only effect, which was followed by an increase in PEPCK-C protein, enzyme activity and glyceroneogenesis.

Conclusions/interpretation

These results favour adipocyte glyceroneogenesis as the initial thiazolidinedione-responsive pathway leading to improvement in dyslipidaemia.
Appendix
Available only for authorised users
Literature
1.
Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:12953–12956PubMedCrossRef
2.
Way JM, Harrington WW, Brown KK et al (2001) Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 142:1269–1277PubMedCrossRef
3.
Oakes ND, Thalen PG, Jacinto SM, Ljung B (2001) Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes 50:1158–1165PubMed
4.
Okuno A, Tamemoto H, Tobe K et al (1998) Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101:1354–1361PubMedCrossRef
5.
Chaput E, Saladin R, Silvestre M, Edgar AD (2000) Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem Biophys Res Commun 271:445–450PubMedCrossRef
6.
Miyazaki Y, Glass L, Triplitt C et al (2001) Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. Diabetologia 44:2210–2219PubMedCrossRef
7.
Mayerson AB, Hundal RS, Dufour S et al (2002) The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51:797–802PubMed
8.
Tan GD, Fielding BA, Currie JM et al (2005) The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Diabetologia 48:83–95PubMedCrossRef
9.
James AP, Watts GF, Mamo JC (2005) The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin-resistant subjects. Diabetes Obes Metab 7:381–389PubMedCrossRef
10.
Boden G, Homko C, Mozzoli M, Showe LC, Nichols C, Cheung P (2005) Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients. Diabetes 54:880–885PubMed
11.
Vaughan M (1962) The production and release of glycerol by adipose tissue incubated in vitro. J Biol Chem 237:3354–3358PubMed
12.
Jensen MD, Ekberg K, Landau BR (2001) Lipid metabolism during fasting. Am J Physiol Endocrinol Metab 281:E789–E793PubMed
13.
Van Harmelen V, Reynisdottir S, Cianflone K et al (1999) Mechanisms involved in the regulation of free fatty acid release from isolated human fat cells by acylation-stimulating protein and insulin. J Biol Chem 274:18243–18251PubMedCrossRef
14.
Beale EG, Hammer RE, Antoine B, Forest C (2002) Glyceroneogenesis comes of age. Faseb J 16:1695–1696PubMedCrossRef
15.
Therriault DG, Hubbard RW, Mellin DB (1969) Endocrine control of fat mobilization in the isolated fat cells of cold-exposed rats. Lipids 4:413–420PubMedCrossRef
16.
Reshef L, Hanson RW, Ballard FJ (1969) Glyceride–glycerol synthesis from pyruvate. Adaptive changes in phosphoenolpyruvate carboxykinase and pyruvate carboxylase in adipose tissue and liver. J Biol Chem 244:1994–2001PubMed
17.
Kruszynska YT, McCormack JG, McIntyre N (1990) Effects of non-esterified fatty acid availability on insulin stimulated glucose utilisation and tissue pyruvate dehydrogenase activity in the rat. Diabetologia 33:396–402PubMedCrossRef
18.
Kalhan SC, Mahajan S, Burkett E, Reshef L, Hanson RW (2001) Glyceroneogenesis and the source of glycerol for hepatic triacylglycerol synthesis in humans. J Biol Chem 276:12928–12931PubMedCrossRef
19.
Tordjman J, Chauvet G, Quette J, Beale EG, Forest C, Antoine B (2003) Thiazolidinediones block fatty acid release by inducing glyceroneogenesis in fat cells. J Biol Chem 278:18785–18790PubMedCrossRef
20.
Duplus E, Benelli C, Reis AF, Fouque F, Velho G, Forest C (2003) Expression of phosphoenolpyruvate carboxykinase gene in human adipose tissue: induction by rosiglitazone and genetic analyses of the adipocyte-specific region of the promoter in type 2 diabetes. Biochimie 85:1257–1264PubMedCrossRef
21.
Leroyer SN, Tordjman J, Chauvet G et al (2006) Rosiglitazone controls fatty acid cycling in human adipose tissue by means of glyceroneogenesis and glycerol phosphorylation. J Biol Chem 281:13141–13149PubMedCrossRef
22.
Bogacka I, Xie H, Bray GA, Smith SR (2004) The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo. Diabetes Care 27:1660–1667PubMed
23.
Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156–159PubMedCrossRef
24.
Chang HC, Lane MD (1966) The enzymatic carboxylation of phosphoenolpyruvate, II. Purification and properties of liver mitochondrial phosphoenolpyruvate carboxykinase. J Biol Chem 241:2413–2420PubMed
25.
Srere PA (1969) Citrate synthase. In: Lowenstein JM (ed) Methods in enzymology XIII. Academic, New York, pp 3–11
26.
Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37:911–917PubMed
27.
Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein–dye binding. Anal Biochem 72:248–254PubMedCrossRef
28.
Dugail I, Quignard-Boulange A, Le Liepvre X, Ardouin B, Lavau M (1992) Gene expression of lipid storage-related enzymes in adipose tissue of the genetically obese Zucker rat. Co-ordinated increase in transcriptional activity and potentiation by hyperinsulinaemia. Biochem J 281(Pt 3):607–611PubMed
29.
Ballard FJ, Hanson RW, Leveille GA (1967) Phosphoenolpyruvate carboxykinase and the synthesis of glyceride–glycerol from pyruvate in adipose tissue. J Biol Chem 242:2746–2750PubMed
30.
Gesta S, Lolmede K, Daviaud D et al (2003) Culture of human adipose tissue explants leads to profound alteration of adipocyte gene expression. Horm Metab Res 35:158–163PubMedCrossRef
31.
Franckhauser-Vogel S, Antras-Ferry J, Robin D, Robin P, Forest C (1997) Transcriptional and posttranscriptional mechanisms of glucocorticoid-mediated repression of phosphoenolpyruvate carboxykinase gene expression in adipocytes. J Cell Biochem 66:386–393PubMedCrossRef
32.
Glorian M, Duplus E, Beale EG, Scott DK, Granner DK, Forest C (2001) A single element in the phosphoenolpyruvate carboxykinase gene mediates thiazolidinedione action specifically in adipocytes. Biochimie 83:933–943PubMedCrossRef
33.
Cadoudal T, Leroyer S, Reis AF et al (2005) Proposed involvement of adipocyte glyceroneogenesis and phosphoenolpyruvate carboxykinase in the metabolic syndrome. Biochimie 87:27–32PubMedCrossRef
34.
Chen JL, Peacock E, Samady W et al (2005) Physiologic and pharmacologic factors influencing glyceroneogenic contribution to triacylglyceride glycerol measured by mass isotopomer distribution analysis. J Biol Chem 280:25396–25402PubMedCrossRef
35.
van Wijk JP, de Koning EJ, Castro Cabezas M, Rabelink TJ (2005) Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes. Diabetes Care 28:844–849PubMed
36.
Antras-Ferry J, Robin P, Robin D, Forest C (1995) Fatty acids and fibrates are potent inducers of transcription of the phosphenolpyruvate carboxykinase gene in adipocytes. Eur J Biochem 234:390–396PubMedCrossRef
37.
Brito SC, Festuccia WL, Kawashita NH et al (2006) Increased glyceroneogenesis in adipose tissue from rats adapted to a high-protein, carbohydrate-free diet: role of dietary fatty acids. Metabolism 55:84–89PubMedCrossRef
38.
Guan HP, Li Y, Jensen MV, Newgard CB, Steppan CM, Lazar MA (2002) A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med 8:1122–1128PubMedCrossRef
39.
Lewis GF, Carpentier A, Adeli K, Giacca A (2002) Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 23:201–229PubMedCrossRef
40.
Riserus U, Tan GD, Fielding BA et al (2005) Rosiglitazone increases indexes of stearoyl-CoA desaturase activity in humans: link to insulin sensitization and the role of dominant-negative mutation in peroxisome proliferator-activated receptor-gamma. Diabetes 54:1379–1384PubMed
41.
Tan GD, Debard C, Funahashi T et al (2005) Changes in adiponectin receptor expression in muscle and adipose tissue of type 2 diabetic patients during rosiglitazone therapy. Diabetologia 48:1585–1589PubMedCrossRef
42.
Tan GD, Debard C, Tiraby C et al (2003) A “futile cycle” induced by thiazolidinediones in human adipose tissue? Nat Med 9:811–812. (author reply 812)PubMedCrossRef
43.
Hallakou S, Doare L, Foufelle F et al (1997) Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 46:1393–1399PubMed
44.
Tontonoz P, Hu E, Devine J, Beale EG, Spiegelman BM (1995) PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol Cell Biol 15:351–357PubMed
45.
Guan HP, Ishizuka T, Chui PC, Lehrke M, Lazar MA (2005) Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes. Genes Dev 19:453–461PubMedCrossRef
Metadata
Title
Acute and selective regulation of glyceroneogenesis and cytosolic phosphoenolpyruvate carboxykinase in adipose tissue by thiazolidinediones in type 2 diabetes
Authors
T. Cadoudal
J. M. Blouin
M. Collinet
F. Fouque
G. D. Tan
E. Loizon
E. G. Beale
K. N. Frayn
F. Karpe
H. Vidal
C. Benelli
C. Forest
Publication date
01-03-2007
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 3/2007
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0560-5

Other articles of this Issue 3/2007

Diabetologia 3/2007 Go to the issue

Article

Expression of the gene encoding the high-K m glucose transporter 2 by the early postimplantation mouse embryo is essential for neural tube defects associated with diabetic embryopathy

Article

Adiponectin receptor genes: mutation screening in syndromes of insulin resistance and association studies for type 2 diabetes and metabolic traits in UK populations

Article

Adiposity, physical fitness and incident diabetes: the physical activity longitudinal study

Short Communication

Soluble thrombomodulin as a predictor of type 2 diabetes: results from the MONICA/KORA Augsburg case–cohort study, 1984–1998

Letter

Comment on: Nathan DM, Buse JB, Davidson MB et al (2006) Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 49:1711–1721

For debate

C-peptide is a bioactive peptide
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits